WO2009148593A1 - Identification and use of prognostic and predictive markers in cancer treatment - Google Patents
Identification and use of prognostic and predictive markers in cancer treatment Download PDFInfo
- Publication number
- WO2009148593A1 WO2009148593A1 PCT/US2009/003382 US2009003382W WO2009148593A1 WO 2009148593 A1 WO2009148593 A1 WO 2009148593A1 US 2009003382 W US2009003382 W US 2009003382W WO 2009148593 A1 WO2009148593 A1 WO 2009148593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- her2
- amplification
- patient
- genes
- breast cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 49
- 201000011510 cancer Diseases 0.000 title abstract description 23
- 238000011282 treatment Methods 0.000 title description 24
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 87
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 86
- 230000003321 amplification Effects 0.000 claims abstract description 83
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 78
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 55
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 50
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 45
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims abstract description 24
- 230000011664 signaling Effects 0.000 claims abstract description 22
- 238000012216 screening Methods 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims description 44
- 229960000575 trastuzumab Drugs 0.000 claims description 40
- 230000008901 benefit Effects 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 24
- 101150054472 HER2 gene Proteins 0.000 claims description 19
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 108091093088 Amplicon Proteins 0.000 abstract description 26
- 239000000523 sample Substances 0.000 abstract description 21
- 238000002493 microarray Methods 0.000 abstract description 13
- 238000004458 analytical method Methods 0.000 abstract description 6
- 238000002372 labelling Methods 0.000 abstract description 6
- 108700020796 Oncogene Proteins 0.000 abstract description 4
- 102000043276 Oncogene Human genes 0.000 abstract description 3
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 51
- 101001126231 Homo sapiens Phospholipid phosphatase 5 Proteins 0.000 description 35
- 102100030452 Phospholipid phosphatase 5 Human genes 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 22
- 238000002512 chemotherapy Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 230000002018 overexpression Effects 0.000 description 17
- 229940022353 herceptin Drugs 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 230000004544 DNA amplification Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 7
- 230000000861 pro-apoptotic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 101000628497 Homo sapiens StAR-related lipid transfer protein 3 Proteins 0.000 description 5
- 102100026719 StAR-related lipid transfer protein 3 Human genes 0.000 description 5
- 238000011226 adjuvant chemotherapy Methods 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 238000011255 standard chemotherapy Methods 0.000 description 4
- 238000011460 HER2-targeted therapy Methods 0.000 description 3
- 108010069394 Phosphatidate Phosphatase Proteins 0.000 description 3
- 102000001107 Phosphatidate Phosphatase Human genes 0.000 description 3
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100033972 Amyloid protein-binding protein 2 Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 101000779309 Homo sapiens Amyloid protein-binding protein 2 Proteins 0.000 description 2
- 101000962438 Homo sapiens Protein MAL2 Proteins 0.000 description 2
- 101000610980 Homo sapiens Tumor protein D52 Proteins 0.000 description 2
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 102100039191 Protein MAL2 Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100040418 Tumor protein D52 Human genes 0.000 description 2
- 102100036595 Zinc finger protein 217 Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100032311 Aurora kinase A Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- -1 CCNDl Proteins 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 1
- 101000870428 Homo sapiens Phospholipase DDHD2 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000013355 Mycteroperca interstitialis Species 0.000 description 1
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100034179 Phospholipase DDHD2 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Definitions
- Breast cancer is a heterogeneous disease with respect to clinical behavior and response to therapy. This variability is a result of the differing molecular make up of cancer cells within each subtype of breast cancer.
- estrogen receptor and HER2 which are targets of antiestrogens (tamoxifen and aromatase inhibitors) and HERCEPTIN® (trastuzumab), respectively.
- Efforts to target these two molecules have proven to be extremely productive. Nevertheless, those tumors that do not have these two targets are often treated with chemotherapy, which generally targets proliferating cells. Since some important normal cells are also proliferating, they are damaged by chemotherapy at the same time. Therefore, chemotherapy is associated with severe toxicity. Identification of molecular targets in tumors in addition to ER or HER2 is critical in the development of new anticancer therapy.
- FISH Fluorescence In situ hybridization
- FDA United States Food and Drug Administration
- FISH probes for potentially important amplified genes have not been comprehensively developed. In fact, there is only one vendor (Vysis, Incorporated, Downers Grove, IL) that supplies an array of probes, but most of these probes have not been clinically validated as prognostic factors. These probes are also very expensive (cost about $300 per case) and of limited variety, barely scratching the repertoire of potentially important amplicons in solid tumors such as breast and colon cancer.
- HER2 protein Approximately 15 to 20% of all breast cancer has overexpression of HER2 protein on its cell surface (Paik, et al., J. Clin. Oncol. 8:103-112, 1990). Such tumors are known to have a worse prognosis than those without HER2 protein overexpression (Paik, et al., supra). Overexpression of HER2 protein is almost invariably due to amplification or increased copy number of the gene encoding HER2.
- HERCEPTIN® (trastuzumab), developed by Genentech.
- HERCEPTIN® has recently been shown to be effective in prolonging survival in patients diagnosed with advanced breast cancer with HER2 overexpression (Slamon, et al, N. Engl. J. Med. 344:783-792, 2001).
- HERCEPTIN® has also been shown to reduce recurrences and death in patients with early stage breast cancer which have HER2 protein overexpression or HER2 gene amplification (Romond, et al, N. Engl. J. Med. 353:1673-1684, 2005).
- cMYC is located on chromosome 8.
- cMYC is expressed in a highly regulated manner driving cells from Gl to S phase.
- efforts to block cMYC has not been a major focus of the pharmaceutical industry, with only one company (Cylene Pharmaceuticals) currently having a drug undergoing clinical testing.
- cMYC has an important role as a molecular switch that determines the fate of the cell to go through programmed cell death or cell proliferation (Pelengaris, et al, Nat. Rev. Cancer 2:764-776, 2002, Pelengaris, et al, Cell 109:321-334, 2002).
- cMYC When cMYC is overexpressed, cells go into uncontrolled cell proliferation and become susceptible to programmed cell death in the absence of a survival signal.
- cMYC induces apoptosis by regulating many components of the programmed cell death pathway, but the main effector seems to be Bax (Pelengaris, et al, Nat. Rev. Cancer supra).
- cMYC overexpression has been shown to cause genomic instability. This could cause amplification of other oncogenes, such as HER2 (Fest, et al, Oncogene 21:2981-2990, 2002). Amplification of other genes could generate anti-apoptotic signals and therefore lead to the inhibition of the apoptotic pathway. For example, in the case of HER2 amplification, studies have demonstrated that HER2 induces Bcl-2, an anti-apoptotic protein that inhibits Bax (Milella, et al, CHn. Cancer Res. 10:7747-7756, 2004).
- the present disclosure describes a number of genes that are predictors of response to HERCEPTIN® (trastuzumab) in an adjuvant setting.
- the disclosed genes thus predict the degree of benefit from trastuzumab added to adjuvant chemotherapy in cancer, and particularly breast cancer.
- cMYC is a predictor of response to HERCEPTIN®, in such a way that for patients with cMYC amplification together with HER2 amplification/overexpression, there is a 75% reduction in cancer recurrence rate when HERCEPTIN® is added to chemotherapy, compared to only 45% reduction in recurrence rate for those patients without cMYC amplification.
- cMYC is amplified in approximately 30% of the breast cancer patients with HER2 amplification or overexpression. Inhibition of HER2 signaling by Trastuzumab apparently changes the cMYC role from proliferation switch to pro-apoptotic switch.
- the invention has the following clinical applications: optimization of methods for patient selection and determining treatments using Trastuzumab and other drugs that target a HER2 signaling pathway: optimization of methods for patient selection for future clinical studies that test the addition of other drugs or targeted therapies, such as Bevacizumab (Avastin) that targets angiogenesis, by allowing identification of patients who are at high risk of relapse even after Trastuzumab or HER2 targeted therapy: PCR-based assay that will detect the gene amplification status of both HER2 and cMYC in a single tube assay for prognostication and prediction of response in breast cancer patients: and rational development of cMYC targeted therapy through indirect modulation of its pro-apoptotic activity by inhibiting anti-apoptotic signal from other activated oncogenes.
- targeted therapies such as Bevacizumab (Avastin) that targets angiogenesis
- the present disclosure also describes a new prognostic and therapeutic target, the HTPAP gene, which when amplified confers poor prognosis in breast cancer patients even after treatment with standard chemotherapy containing doxorubicin, cyclophosphamide, and paclitaxel.
- HTPAP amplification is an independent prognosticator of tumor size, treatment, number of positive axillary lymph nodes, age and hormone receptor status, HER2 amplification, and cMYC amplification.
- the present disclosure also provides methods for treating a patient having breast cancer, comprising measuring the expression level or amplification of one or more of the genes listed in Tables 5-14 in a patient having breast cancer, and providing a patient having increased expression level or amplification of one or more of the genes listed in Tables 5-14 with a therapeutically effective amount of a combination of one or more adjuvant chemotherapeutic compounds and at least one compound that inhibits the activity, amount, or signaling of HER2.
- genes are referenced by a number of different methods, including gene symbol, genomic coordinates, and GenBank accession numbers. It is well-known to those of skill in the art that any of these identification methods is sufficient to identify a specific gene, and thus these identification methods are considered to be interchangable. Therefore, a skilled artisan provided with a GenBank accession number can readily determine the identity of the referenced gene utilizing the publically available web site of the National Center for Biotechnology Information ("NCBI").
- NCBI National Center for Biotechnology Information
- increased expression or amplification of two, three, four, five, six, seven, eight, nine, ten eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, or fifty genes or more listed in Tables 5-14 is indicative of a patient that would benefit from the administration of a compound that inhibits the activity, amount, or signaling of HER2 in an adjuvant chemotherapeutic setting.
- the present disclosure also provides assays that can be used to identify patients that would benefit from administration of a compound that inhibits the activity, amount, or signaling of HER2.
- gene expression levels can be measured by any of the numerous methods known to those of skill in the art, including, but not limited to, an enzyme-linked immunosorbent assay, a radioimmunoassay, flow cytometery, or real time quantitative polymerase chain reaction assay. Furthermore, any method of measuring or determining gene amplification can be used with the disclosed methods, including, but not limited to, fluorescent in situ hybridization.
- the compound that inhibits the activity, amount, or signaling of HER2 is an anti-HER2 antibody, a HER2 antisense molecule, a HER2 small inhibitory RNA molecule ("siRNA"), or a small molecule inhibitor of HER2.
- the anti-HER2 antibody may be an anti-HER2 monoclonal antibody, including, but not limited to, trastuzumab.
- the presently disclosed treatment methods can be utilized in conjunction with a single adjuvant chemotherapeutic compound, or a plurality of adjuvant chemotherapeutic compounds.
- Chemotherapeutic compounds that can be used in conjunction with the disclosed methods include, but are not limited to, doxorubicin, cyclophosphamide, and paclitaxel, and combinations thereof.
- treatment of cancer patients with a combination of adjuvant chemotherapy and a compound that inhibits the activity, amount, or signaling of HER2 provides a significant benefit even to patients that do not have increased expression or amplification of the HER2 gene.
- the patient can be screened for increased expression or amplification of the HER2 gene.
- the presently disclosed treatment methods will provide a benefit to patients that have increased expression or amplification of the HER2 gene, as well as patients that do not have increased expression or amplification of the HER2 gene.
- the present disclosure also provides methods of identifying or diagnosing a patient with breast cancer undergoing adjuvant therapy that would benefit from administration of a compound that inhibits the activity, amount, or signaling of HER2, comprising measuring the expression level or amplification of one or more of the genes listed in Tables 5-14 in the patient, wherein an increased expression level or amplification of one or more of the genes listed in Tables 5-14 is indicative of a patient with breast cancer undergoing adjuvant therapy that would benefit from administration of a compound that inhibits the activity, amount, or signaling of HER2.
- the terms “treat,” “treating,” and “treatment” contemplate an action that occurs while a patient is suffering from a disease or disorder, that reduces the severity of one or more symptoms or effects of the disease or disorder, or a related disease or disorder.
- the terms “manage,” “managing,” and “management” encompass preventing, delaying, or reducing the severity of a recurrence of a disease or disorder in a patient who has already suffered from the disease or disorder. The terms encompass modulating the threshold, development, and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.
- a "therapeutically effective amount" of a compound is an amount sufficient to provide any therapeutic benefit in the treatment or management of a disease or disorder, or to delay or minimize one or more symptoms associated with a disease or disorder.
- a therapeutically effective amount of a compound means an amount of the compound, alone or in combination with one or more other therapy and/or therapeutic agent, which provides any therapeutic benefit in the treatment or management of a disease or disorder, or related diseases or disorders.
- the term "therapeutically effective amount” can encompass an amount that cures a disease or disorder, improves or reduces a disease or disorder, reduces or avoids symptoms or causes of a disease or disorder, improves overall therapy, or enhances the therapeutic efficacy of another therapeutic agent.
- BAC directly fluorescence labeling bacterial artificial clones
- This disclosure provides a method for fluorescently labeling BAC clones representing known amplicons efficiently by combining a series of whole genome amplification methods and an efficient FISH method for paraffin embedded tissue which has been archived more than 10 years. Briefly, the literature and array CGH data is reviewed, and candidate amplicons (-50) are selected. BAC clones from public sources that correspond to the candidate amplicons are obtained and labeled for FISH analysis of tissue microarrays ("TMAs”) constructed from a tissue bank containing over 30,000 samples created from National Surgical Adjuvant Breast and Bowel Project (“NSABP”) trials.
- TMAs tissue microarrays
- NSABP National Surgical Adjuvant Breast and Bowel Project
- the data is used for clinical correlation and model building, and validated using an independent data set TMA from NSABP.
- This labeling and FISH method is a log order less expensive as compared to commercially available probes.
- Using paraffin block tissue samples for over 30,000 breast and colon cancer cases that are all annotated with clinical follow-up information and treatment received provided a unique source for clinical correlative science studies.
- Combining the FISH method with tissue microarrays allows screening of more than 100 cases using a single microscopic section, making screening of multiple amplicons in thousands of cases a reality.
- any number of methods well-known in the art can be used to label probes for FISH applications.
- FISH FISH is used to determine amplification
- numerous other quantitative or semi-quantitative methods may be used, including, but not limited to, antibody based assays (such as ELISA (enzyme-linked immunosorbent assay)) and qtPCR. Pilot Project:
- tissue microarrays were constructed and FISH assays performed for 10 different in-house developed probes based on array CGH data (two sets are very close to each other: HER2 and MLN64; and APPBP2 and PPMlD). The amplicons and their chromosomal locations are shown in Table 1.
- amplicons were based on the following criteria: 1) selected amplicons had all been shown to be associated with moderate to high level of gene expression of the coded genes when amplified in breast cancer tumors or cell lines in studies mentioned previously (Pollack, et al., supra, and Hyman, et al, supra); 2) the public genome sequence map was examined and FISH-validated BAC clones were selected that corresponded best with the selected amplicons; and 3) some amplicons, such as MLN64, which were located very close to HER2, were included as an internal control for reproducibility and validity of the assay (that is, HER2 and MLN64 amplification were expected to correlate extremely tightly due to their close proximity in chromosome location).
- Amplification status was categorized as either amplified or non-amplified, with gene amplification defined as having more than 4 signals (4 dots per single tumor cell nucleus) from in situ hybridization.
- Correlation with clinical outcome using univariate Cox proportional hazard model showed that HER2, MLN64 (which is very close to HER2 and highly correlated), cMYC, HTPAP, TPD52, MAL2, and ZNF217 are significantly correlated with clinical outcome of patients entered into the B-28 trial (Table 3).
- the presence of any amplification and number of amplifications also showed significant correlation with outcome.
- Multivariate analysis including conventional prognostic markers (tumor size, number of positive nodes, hormone receptor status, and age) was performed. Three amplicons remained significant: HER2; cMYC; and HTPAP (Table 4).
- HER2, cMYC, and HTPAP are three independent amplified genes that confer a worse prognosis, even after standard combination taxane- containing adjuvant chemotherapy. Furthermore, cases that had co-amplification of HER2 and cMYC had a much worse prognosis than cases with amplification of either one of the genes alone.
- HTPAP HTPAP
- HTPAP is a novel gene that translates into a protein with a phosphatidic acid phosphatase homology domain and a 5' transmembrane domain, as well as a signal peptide that indicates that the protein product is secreted.
- the BAC clone used for generation of FISH probe for HTPAP (clone RP11-513D5) has only three genes in it: HTPAP; WHSClLl; and DDHD2. Of these, other studies correlating gene amplification with expression in breast cancer cell lines have shown that HTPAP is the one that is overexpressed when this region is amplified (Pollack, et al, supra, Hyman, et al, supra, Ray, et al, Cancer Res.
- HTPAP is amplified, and stable clinical diagnostic assay using FISH or PCR can be used to detect the amplification status; 2) it is an independent prognostic factor in heavily treated patients; 3) it is a transmembrane protein with enzyme activity; and 4) it is also secreted.
- the amplification of HTPAP being highly correlated with poor prognosis indicates that blocking of these activities will have beneficial therapeutic effects (as exemplified by the HER2 gene, which has similar characteristics of being amplified, a prognostic factor, and a cell surface receptor).
- Certain embodiments of the present invention include monoclonal antibodies or series of monoclonal antibodies with specificity for the extracellular domain of the HTPAP protein. These antibodies can be used either alone or in combination with chemotherapeutic drugs or antibodies to other targets. The generation of such antibodies can be performed via any number of methods for monoclonal production which are well known in the art.
- these anti-HTPAP antibodies are used to detect HTPAP protein secreted in the serum, plasma, or other body fluid (such as nipple aspirate from the patients), and compared to normal levels in the diagnosis or monitoring of disease during therapy. Detection may be accomplished by any number of methods well known in the art, including, but not limited to, radioimmunoassay, flow cytometery, ELISA, or other colormetric assays.
- Phosphatidic acid phosphatase domains typically act as an important signaling molecule in cancer cells. Certain embodiments of the present invention include the use of these domains of the HTPAP gene in targeting and development of small molecules that interfere or modulate such activity. Furthermore, the use of antibodies to HTPAP can be used to identify signaling molecules downstream to HTPAP, which can be subsequently targeted by small molecule therapeutics. Certain other embodiments include blocking HTPAP gene activity using siRNA, antisense oligonucleotide, or ribozyme approaches, which are well known in the art.
- the present disclosure provides methods of treating breast cancer that include measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP.
- genes found to be of marginal prognostic power in this study cohort of AC- or ACT-treated node positive breast cancer may have significant prognostic power in untreated or node negative patients. These include TPD52, MAL2, ZNF217, NCOA3, ZHXl, BM_009, BMP7, and STK6, and thus these genes may also provide attractive target for therapeutic development.
- three prognostic amplified genes HER2, cMYC, and HTPAP
- HER2, cMYC, and HTPAP can be utilized to create a prognostic index to guide treatment decision making for breast cancer patients.
- Certain other embodiments include HER2, cMYC, and HTPAP together with clinical variables to generate a prognostic index to guide treatment decision making.
- cMYC The status of cMYC in 1344 patients enrolled in the NSABP B-31 trial were examined to test the potential benefits of addition of trastuzumab to chemotherapy in the treatment of patients diagnosed with early stage breast cancer with HER2 gene amplification/overexpression.
- FISH was used to enumerate the cMYC gene copy number using a commercially available DNA probe (Vysis, Incorporated). Any tumor with more than 10% of cells showing more than 4 copies of cMYC gene was classified as cMYC gene amplified in this analysis. Out of a total of 1344 cases studied, 399 cases were classified as cMYC amplified.
- Tumors with cMYC amplification were believed to be sensitive to inhibition of HER2 signaling due to its activation of a pro-apoptotic signal when the HER2 signal is inhibited by trastuzumab, and that this would translate into a much more significant reduction in recurrence rate in cMYC amplified cohort in comparison to patients with no amplification of cMYC.
- trastuzumab does not cure all HER2 overexpressing tumors
- strategies to add other targeted therapies such as an inhibitor of angiogenesis may be useful.
- an approach is highly toxic and very expensive.
- Patients undergoing chemotherapy having amplification of cMYC should not need additional therapy (other than trastuzumab), due to their sensitivity to trastuzumab. Therefore, one invention of the present disclosure is the screening of patients for approaches that add other targeted therapies to trastuzumab.
- the present disclosure includes a method of determining the cMYC and HER2 amplification status of cancer patients.
- the present disclosure is also applicable to other HER2-targeted therapies, since the effect is an indirect one through activation of the pro- apoptotic role of cMYC.
- the invention disclosed herein includes methods of determining treatments and treating patients with trastuzumab and other materials based on the status of cMYC and HER2 in a patient.
- the present invention can be applied in exploiting the pro-apoptotic function of cMYC in cMYC-amplified tumors without HER2 amplification.
- indirect approaches inhibiting survival signals will likely make such tumors go through programmed cell death by activation of the pro-apoptotic function of cMYC.
- the test for cMYC in the present disclosure can be either in the format of FISH, quantitative polymerase chain reaction, immunohistochemistry, or other immunological detection method in homogenized tumor tissue, including a single tube, "real-time” quantitative polymerase chain reaction (“qtPCR") assay that includes HER2, cMYC, HTPAP, and a reference gene to simultaneously detect the presence of amplification of these three genes and provide both prognostic information as well as prediction of response to trastuzumab or other HER2 -targeted therapies, as well assays and methods of treating a patient based on the results of such an assay.
- qtPCR quantitative polymerase chain reaction
- the NSABP B-31 trial compared the benefit of adding trastuzumab to standard adjuvant ACT chemotherapy (Romond, et ai, supra). While all of the originally intended study population was supposed to be positive for HER2 gene amplification or HER2 protein overexpression, about 10% of them were HER2 negative. However, the HER2 negative population still gained significant clinical benefit from adding trastuzumab to standard adjuvant ACT chemotherapy. Thus, HER2 gene copy number was not predictive of the degree of benefit from trastuzumab. This data suggested that there should be other molecular markers that dictate the response to trastuzumab.
- Tumor blocks were submitted for 1829 of the 2043 patients enrolled in the NSABP B- 31 trial, all of whom had provided informed consent. Among these, 1795 had available information on clinical follow-up, number of positive nodes, and estrogen receptor status of the tumors.
- microarray gene expression analyses of the formalin fixed paraffin embedded tumor blocks are being carried out in a three step effort: 1) discover predictive genes; 2) refine the gene list in an independent cohort; and 3) final prospective testing of a predictive model in yet another independent cohort.
- RNA extracted from paraffin blocks were amplified and hybridized to Agilent 4x44 arrays.
- a commercial kit was used for RNA extraction (Ambion) and RNA was amplified with Transplex whole transcriptome amplification kit (Rubicon Genomics).
- the resulting amplified cDNA was labeled with either biotin or cy-3 fluorescence dye before hybridizing to an Affymetrix or Agilent microarray.
- the hybridization signals were obtained by scanning with scanners from Affymetrix and Agilent respectively.
- the raw data was processed and normalized with commercially available software Partek Genomic Suite (Partek). Expression levels for each gene probe were dichotomized using median cut, hazard ratios for treatment arms were calculated, and interaction tests were performed.
- the normalized expression data for each gene was correlated with clinical outcome to test for prediction of degree of benefit from adding trastuzumab to chemotherapy using Cox proportional hazard model.
- the measure of prediction was expressed in "p-value for interaction.” Any gene that showed p-value for interaction below 0.05 was regarded as significantly predictive of the degree of benefit from trastuzumab. Since studies with a sample size of 400 could be underpowered to detect interaction at a significance level of 0.05 even if there is true interaction, when looking for genes that are predictive in both cohorts, genes that are significant in one cohort at 0.05 level and at 0.1 level in the other cohorts were noted. Genes that are significant at 0.05 level in all three experiments provided the set of genes with the most confidence.
- Table 5 shows the results from the Agilent Second Cohort.
- Table 8 lists first cohort genes that were 0.05 in either the Affymetrix or Agilent screening and 0.1 in the other.
- Table 9 lists first cohort genes that were 0.05 in both Affymetrix and Agilent screening.
- Table 10 lists genes that were 0.05 in at least 1 experiment and 0.1 in the other two experiments.
- prognostic genes for chemotherapy patients based on the data from the extended study of 753 patients using Agilent microarrays are listed in Table 13, and prognostic genes for herceptin patients based on the data from the extended study of 753 patients using Agilent microarrays are listed in Table 14.
- HER2 was not the main determinant of the degree of benefit from trastuzumab added to adjuvant chemotherapy. Without being held to any specific mechanism of action, Applicants believe that this could be due to the fact that HER2 positive tumors are sensitive to the legacy treatment (chemohormonal therapy) and disseminated tumor cells may express different levels of HER2 in the index tumor (see, e.g., Gangnus, et al., CHn. Cancer Res. 10:3457-3463, 2004, Schardt, et al., Cancer Cell 8:227-239, 2005, and Ignatiadis, et al, Clin. Cancer Res. 14:2593-2600, 2008).
- Prediction of the degree of benefit from trastuzumab added to chemotherapy may be quite different from predicting tumor response in a metastatic or neoadjuvant setting where direct tumor shrinkage is measured. This data has broad implications on development of targeted therapies in an adjuvant setting.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2726817A CA2726817A1 (en) | 2008-06-02 | 2009-06-02 | Identification and use of prognostic and predictive markers in cancer treatment |
EP09758757A EP2304053A1 (en) | 2008-06-02 | 2009-06-02 | Identification and use of prognostic and predictive markers in cancer treatment |
AU2009255599A AU2009255599A1 (en) | 2008-06-02 | 2009-06-02 | Identification and use of prognostic and predictive markers in cancer treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13067808P | 2008-06-02 | 2008-06-02 | |
US61/130,678 | 2008-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009148593A1 true WO2009148593A1 (en) | 2009-12-10 |
Family
ID=41398399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/003382 WO2009148593A1 (en) | 2008-06-02 | 2009-06-02 | Identification and use of prognostic and predictive markers in cancer treatment |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090304697A1 (en) |
EP (1) | EP2304053A1 (en) |
KR (1) | KR20110018930A (en) |
AU (1) | AU2009255599A1 (en) |
CA (1) | CA2726817A1 (en) |
WO (1) | WO2009148593A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011086174A3 (en) * | 2010-01-15 | 2011-10-06 | Diagenic Asa | Diagnostic gene expression platform |
WO2012023286A1 (en) * | 2010-08-19 | 2012-02-23 | Oncotherapy Science, Inc. | Lrrc42 as a target gene for cancer therapy and diagnosis |
WO2012147800A1 (en) * | 2011-04-25 | 2012-11-01 | 東レ株式会社 | Composition for predicting sensitivity to trastuzumab therapy in breast cancer patients and method using same |
US9212228B2 (en) | 2005-11-24 | 2015-12-15 | Ganymed Pharmaceuticals Ag | Monoclonal antibodies against claudin-18 for treatment of cancer |
US9512232B2 (en) | 2012-05-09 | 2016-12-06 | Ganymed Pharmaceuticals Ag | Antibodies against Claudin 18.2 useful in cancer diagnosis |
US9775785B2 (en) | 2004-05-18 | 2017-10-03 | Ganymed Pharmaceuticals Ag | Antibody to genetic products differentially expressed in tumors and the use thereof |
EP3134549A4 (en) * | 2014-04-21 | 2017-11-22 | Mayo Foundation for Medical Education and Research | Methods and materials for identifying and treating mammals having her2-positive breast cancer |
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
US10813996B2 (en) | 2012-05-23 | 2020-10-27 | Astellas Pharma Inc. | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501483B2 (en) * | 2008-04-14 | 2013-08-06 | University College Dublin, National University Of Ireland, Dublin | Method of assessing cancer status in a breast cancer patient |
US10648035B2 (en) | 2012-11-26 | 2020-05-12 | The Johns Hopkins University | Methods and compositions for diagnosing and treating gastric cancer |
WO2014130617A1 (en) * | 2013-02-22 | 2014-08-28 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
CN103913576B (en) * | 2013-05-07 | 2016-03-16 | 上海良润生物医药科技有限公司 | The application of Cystatin SN and CA15-3 in preparation diagnosis and indication markers for breast cancer |
CN114870017A (en) * | 2022-05-07 | 2022-08-09 | 温州医科大学附属第六医院 | Application of TMEM100 in regulation of 5-fluorouracil resistance of lung cancer |
CN115992217B (en) * | 2022-09-30 | 2023-09-22 | 中国人民解放军总医院第二医学中心 | Annular RNA marker for diagnosing myocardial damage caused by breast cancer chemotherapy, kit and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127935A1 (en) * | 2004-12-15 | 2006-06-15 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
-
2009
- 2009-06-02 WO PCT/US2009/003382 patent/WO2009148593A1/en active Application Filing
- 2009-06-02 EP EP09758757A patent/EP2304053A1/en not_active Withdrawn
- 2009-06-02 CA CA2726817A patent/CA2726817A1/en not_active Abandoned
- 2009-06-02 AU AU2009255599A patent/AU2009255599A1/en not_active Abandoned
- 2009-06-02 KR KR1020107029865A patent/KR20110018930A/en not_active Application Discontinuation
- 2009-06-02 US US12/455,551 patent/US20090304697A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127935A1 (en) * | 2004-12-15 | 2006-06-15 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
Non-Patent Citations (2)
Title |
---|
CALLAGY ET AL: "Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays", JOURNAL OF PATHOLOGY, vol. 205, no. 3, February 2005 (2005-02-01), pages 388 - 396, XP002444116 * |
KONECNY ET AL: "Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2- Overexpressing and Trastuzumab-Treated Breast Cancer Cells", CANCER RES, vol. 66, no. 3, 1 February 2006 (2006-02-01), pages 1630 - 1639, XP002472825 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10414824B2 (en) | 2002-11-22 | 2019-09-17 | Ganymed Pharmaceuticals Ag | Genetic products differentially expressed in tumors and the use thereof |
US9775785B2 (en) | 2004-05-18 | 2017-10-03 | Ganymed Pharmaceuticals Ag | Antibody to genetic products differentially expressed in tumors and the use thereof |
US10017564B2 (en) | 2005-11-24 | 2018-07-10 | Ganymed Pharmaceuticals Gmbh | Monoclonal antibodies against claudin-18 for treatment of cancer |
US11739139B2 (en) | 2005-11-24 | 2023-08-29 | Astellas Pharma Inc. | Monoclonal antibodies against Claudin-18 for treatment of cancer |
US10738108B2 (en) | 2005-11-24 | 2020-08-11 | Astellas Pharma Inc. | Monoclonal antibodies against claudin-18 for treatment of cancer |
US9212228B2 (en) | 2005-11-24 | 2015-12-15 | Ganymed Pharmaceuticals Ag | Monoclonal antibodies against claudin-18 for treatment of cancer |
US9499609B2 (en) | 2005-11-24 | 2016-11-22 | Ganymed Pharmaceuticals Ag | Monoclonal antibodies against claudin-18 for treatment of cancer |
US9751934B2 (en) | 2005-11-24 | 2017-09-05 | Ganymed Pharmaceuticals Ag | Monoclonal antibodies against claudin-18 for treatment of cancer |
US10174104B2 (en) | 2005-11-24 | 2019-01-08 | Ganymed Pharmaceuticals Gmbh | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2011086174A3 (en) * | 2010-01-15 | 2011-10-06 | Diagenic Asa | Diagnostic gene expression platform |
WO2012023286A1 (en) * | 2010-08-19 | 2012-02-23 | Oncotherapy Science, Inc. | Lrrc42 as a target gene for cancer therapy and diagnosis |
JP6026408B2 (en) * | 2011-04-25 | 2016-11-16 | 東レ株式会社 | Composition and method for predicting therapeutic sensitivity to trastuzumab in breast cancer patients |
US9873916B2 (en) | 2011-04-25 | 2018-01-23 | Toray Industries, Inc. | Method for predicting response to trastuzumab therapy in breast cancer patients |
CN103492566A (en) * | 2011-04-25 | 2014-01-01 | 东丽株式会社 | Composition for predicting sensitivity to trastuzumab therapy in breast cancer patients and method using same |
WO2012147800A1 (en) * | 2011-04-25 | 2012-11-01 | 東レ株式会社 | Composition for predicting sensitivity to trastuzumab therapy in breast cancer patients and method using same |
US10053512B2 (en) | 2012-05-09 | 2018-08-21 | Ganymed Pharmaceuticals Ag | Antibodies against claudin 18.2 useful in cancer diagnosis |
US9512232B2 (en) | 2012-05-09 | 2016-12-06 | Ganymed Pharmaceuticals Ag | Antibodies against Claudin 18.2 useful in cancer diagnosis |
US11976130B2 (en) | 2012-05-09 | 2024-05-07 | Astellas Pharma Inc. | Antibodies against claudin 18.2 useful in cancer diagnosis |
US10813996B2 (en) | 2012-05-23 | 2020-10-27 | Astellas Pharma Inc. | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer |
EP3134549A4 (en) * | 2014-04-21 | 2017-11-22 | Mayo Foundation for Medical Education and Research | Methods and materials for identifying and treating mammals having her2-positive breast cancer |
Also Published As
Publication number | Publication date |
---|---|
CA2726817A1 (en) | 2009-12-10 |
AU2009255599A1 (en) | 2009-12-10 |
US20090304697A1 (en) | 2009-12-10 |
KR20110018930A (en) | 2011-02-24 |
EP2304053A1 (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009148593A1 (en) | Identification and use of prognostic and predictive markers in cancer treatment | |
Jansen et al. | Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling | |
Jansen et al. | Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease | |
JP6144695B2 (en) | How to treat breast cancer with taxane therapy | |
US20130004970A1 (en) | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients | |
JP2015057055A (en) | Tumor grading and cancer prognosis | |
JP2008524986A (en) | Genetic changes useful for predicting malignant tumor response to taxane-based drug therapy | |
Schneider et al. | Identification and meta‐analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer | |
Baehner et al. | Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy | |
US20120329878A1 (en) | Phenotyping tumor-infiltrating leukocytes | |
US20090035311A1 (en) | Identification and use of prognostic and predictive markers in cancer treatment | |
Koutras et al. | Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study | |
Aftimos et al. | Molecular biology of breast cancer | |
CA2753971A1 (en) | Accelerated progression relapse test | |
Dunn et al. | Genomic predictors of outcome and treatment response in breast cancer | |
KR102403807B1 (en) | Biomarker predictive of responsiveness to an anticancer agent and use thereof | |
US20140100188A1 (en) | Phenotyping tumor-infiltrating leukocytes | |
WO2020251645A1 (en) | 7-gene prognostic and predictive assay for non-small cell lung cancer in formalin fixed and paraffin embedded samples | |
Mallmann et al. | Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients | |
Lin et al. | The role of miR-145-5p in esophageal squamous cell carcinoma tumor-associated macrophages and selection of immunochemotherapy | |
Koutras et al. | Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study | |
Nigon et al. | Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network | |
Calhoun et al. | MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy | |
Kotoula et al. | Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17 | |
US20130251710A1 (en) | Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09758757 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2726817 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009255599 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009758757 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107029865 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009255599 Country of ref document: AU Date of ref document: 20090602 Kind code of ref document: A |